MDACC Study No:2007-0512 ( NCT No: NCT00520208)
Title:A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1)
Principal Investigator:Jorge Cortes
Treatment Agent:Tamibarotene
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out if tamibarotene can
help to control APL. The safety of this treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Tamibarotene
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:n/a
Supported By:CytRx Corporation
Return Visit:During induction therapy every 7 days for 57 days. For consolidation therapy
every 14 days, every other month for 6 months.
Home Care:n/a

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults